>MNTA – Are you impressed by the composition of this Board?<
Impressed is an understatement. I would submit that there is not a more credentialed BoD in all of biotech.
If there is one knock on MNTA’s BoD, it’s that only four of the eleven directors are fully independent. Normally, I’d be concerned about this insofar as an insular BoD may find it hard to stand up to a CEO when a new direction—or new leadership—becomes imperative. However, in this case the CEO himself is a new kid on the block and I very much doubt the BoD would have any problem clipping his wings if need be.
Moreover, I like the fact that the BoD contains an assortment of VC’s who have serious money on the line even while no single VC comes close to having control of the company. (The largest shareholder, with a 13% stake, is Novartis.)
All told, MNTA’s BoD is about as good as it gets, IMO.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”